Radius Health Inc Can’t Burn Your Long Portfolio. Option Traders are Bullish

 Radius Health Inc Can't Burn Your Long Portfolio. Option Traders are Bullish

In today’s session Radius Health Inc (RDUS) registered an unusually high (933) contracts volume of call trades. Someone, most probably a professional was a very active buyer of the October, 2016 call, expecting serious RDUS increase. With 933 contracts traded and 13344 open interest for the Oct, 16 contract, it seems this is a quite bullish bet. The option with symbol: RDUS161021C00070000 closed last at: $1.15 or 155.6% up. About 409,689 shares traded hands. Radius Health Inc (NASDAQ:RDUS) has risen 66.86% since March 15, 2016 and is uptrending. It has outperformed by 61.38% the S&P500.

Analysts await Radius Health Inc (NASDAQ:RDUS) to report earnings on November, 3. They expect $-1.04 earnings per share, down 52.94% or $0.36 from last year’s $-0.68 per share. After $-1.01 actual earnings per share reported by Radius Health Inc for the previous quarter, Wall Street now forecasts 2.97% negative EPS growth.

Radius Health Inc (NASDAQ:RDUS) Ratings Coverage

Out of 9 analysts covering Radius Health (NASDAQ:RDUS), 7 rate it a “Buy”, 0 “Sell”, while 2 “Hold”. This means 78% are positive. Radius Health has been the topic of 13 analyst reports since August 7, 2015 according to StockzIntelligence Inc. The firm has “Buy” rating given on Monday, May 23 by H.C. Wainwright. The firm has “Hold” rating given on Wednesday, February 24 by Jefferies. JP Morgan initiated Radius Health Inc (NASDAQ:RDUS) rating on Friday, October 2. JP Morgan has “Overweight” rating and $88 price target. Goldman Sachs initiated the stock with “Neutral” rating in Wednesday, March 30 report. The rating was reinitiated by Cowen & Co on Friday, May 6 with “Outperform”. Deutsche Bank initiated it with “Buy” rating and $90 target price in Friday, August 14 report. H.C. Wainwright maintained Radius Health Inc (NASDAQ:RDUS) rating on Wednesday, September 21. H.C. Wainwright has “Buy” rating and $71 price target. The stock of Radius Health Inc (NASDAQ:RDUS) has “Buy” rating given on Thursday, September 24 by Canaccord Genuity.

According to Zacks Investment Research, “Radius Health Inc. is a science-driven biopharmaceutical company. It is focused on developing novel differentiated therapeutics for patients with osteoporosis as well as other serious endocrine-mediated diseases. The Company’s lead product candidate, abaloparatide (BA058), is in development, in both injection (Abaloparatide-SC) and transdermal (Abaloparatide-TD) methods of administration, for the prevention of fractures in post-menopausal women at risk of fracture from osteoporosis. Radius Health Inc. is based in Cambridge, Massachusetts.”

Insitutional Activity: The institutional sentiment increased to 1.32 in 2016 Q2. Its up 0.03, from 1.29 in 2016Q1. The ratio increased, as 20 funds sold all Radius Health Inc shares owned while 33 reduced positions. 22 funds bought stakes while 48 increased positions. They now own 42.68 million shares or 5.94% more from 40.29 million shares in 2016Q1.
Lpl Financial Limited Liability Corporation accumulated 7,396 shares or 0% of the stock. Credit Suisse Ag last reported 0.01% of its portfolio in the stock. Jennison Assocs Ltd Co, a New York-based fund reported 964,142 shares. American Gp has 0% invested in the company for 18,166 shares. Rhumbline Advisers accumulated 32,418 shares or 0% of the stock. Brookside Cap Mgmt Limited Liability Corporation holds 3.34M shares or 5.14% of its portfolio. State Board Of Administration Of Florida Retirement Sys owns 21,248 shares or 0% of their US portfolio. Group Incorporated One Trading Lp, a Illinois-based fund reported 58,267 shares. Millennium Management Limited Liability Co accumulated 0.01% or 99,319 shares. Glob X Mngmt Limited Com holds 0% or 124 shares in its portfolio. Zurcher Kantonalbank (Zurich Cantonalbank) holds 0% of its portfolio in Radius Health Inc (NASDAQ:RDUS) for 616 shares. Aqr Cap Mngmt Limited Liability Co accumulated 0% or 28,380 shares. Neuberger Berman Group Ltd holds 12,500 shares or 0% of its portfolio. Nicholas Invest Prns L P has invested 0.16% of its portfolio in Radius Health Inc (NASDAQ:RDUS). Alps Advisors, a Colorado-based fund reported 60,460 shares.

Radius Health, Inc. is a biopharmaceutical firm focused on developing therapeutics in the areas of osteoporosis, oncology and endocrine diseases. The company has a market cap of $2.19 billion. The Company’s product candidate, the investigational drug abaloparatide for subcutaneous injection, has completed Phase III development for use in the reduction of fracture risk in postmenopausal women with osteoporosis. It currently has negative earnings. The Company’s clinical pipeline also includes an investigational abaloparatide transdermal patch for use in osteoporosis and the investigational drug RAD1901 for use in hormone-driven and hormone-resistant breast cancer, and vasomotor symptoms in postmenopausal women.

RDUS Company Profile

Radius Health, Inc. is a biopharmaceutical firm focused on developing therapeutics in the areas of osteoporosis, oncology and endocrine diseases. The Company’s product candidate, the investigational drug abaloparatide for subcutaneous injection, has completed Phase III development for use in the reduction of fracture risk in postmenopausal women with osteoporosis. The Company’s clinical pipeline also includes an investigational abaloparatide transdermal patch for use in osteoporosis and the investigational drug RAD1901 for use in hormone-driven and hormone-resistant breast cancer, and vasomotor symptoms in postmenopausal women. The Company’s preclinical pipeline includes RAD140, a non-steroidal, selective androgen receptor modulator (SARM) under investigation for use in cancer.

More recent Radius Health Inc (NASDAQ:RDUS) news were published by: Fool.com which released: “Why Radius Health Inc. Dropped 45% in January” on February 08, 2016. Also Fool.com published the news titled: “Why Radius Health Inc. is Screaming Higher Today” on February 22, 2016. Philly.com‘s news article titled: “Radius Health eyes drug launch, expands in Wayne” with publication date: June 22, 2016 was also an interesting one.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Tags: , ,

Related posts

Leave a Comment